TMCNet:  The 13th Annual BIO Investor Forum to Host Over 100 Presenting Companies

[August 25, 2014]

The 13th Annual BIO Investor Forum to Host Over 100 Presenting Companies

WASHINGTON --(Business Wire)--

The Biotechnology Industry Organization (BIO) today announced the initial list of presenting companies for the 13th Annual BIO Investor Forum. The event is an international investor forum that assembles early and established private companies as well as emerging public biotechs, along with top public and private equity investors, to explore investment trends and opportunities in life sciences. The event will take place October 7-8, 2014 at the Palace Hotel in San Francisco, California.

"Over the past three years, more than 30 of the private companies that presented at a BIO Investor Forum have gone public, generating a current combined market capitalization of nearly $15 billion," said Jim Greenwood, CEO and President at BIO. "Investors are eager to learn about and evaluate fresh new investment opportunities, as evidenced by the 30% increase in investor registration to date compared to last year."

Presenting companies have a clear R&D focus with a pipeline involving biotechnology for therapeutics, diagnostics or platform technologies. More than one-quarter of the public presenting companies at the event have gone public since passage of the Jumpstart Our Business Startups (JOBS) Act in April 2012. To date, overall, 111 biotech companies have gone public since passage of the JOBS Act.

New presenting companies are continuously being added. For updates on the list of presenters, please visit here. If you are interested in becoming a presenter, please submit an application here.

The following companies will present at the 13th Annual BIO Investor Forum:

AbGenomics International
Actogenix NV
Aduro Biotech
BEAT BioTherapeutics
Blueprint Medicines
Cebix, Inc.
CoLucid Pharmaceuticals
Critical Outcome Technologies Inc.
CytomX Therapeutics
Ennaid Therapeutics
Evgen Pharma
Genkyotex SA
Immatics Biotechnologies
Isarna Therapeutics
Juventas Therapeutics
Kadmon Corporation
Maverix Bomics
MAX BioPharma
MiNA Therapeutics
Mirna Therapeutics
Neumedicines Inc.
NuvOx Pharma
Protagonist Therapeutics, Inc.
Provista Diagnostics
Sutro Biopharma
Vascular Pharmaceuticals
Vivaldi Biosciences Inc.

Apricus Bioscience
Arno Therapeutics

Bio-Path Holdings
Catalyst Pharmaceutical Partners
Celladon Corporation*
ContraFect Corporation*
Critical Outcome Technologies
CymaBay Therapeutics
Dicerna Pharmaceuticals*
Heat Biologics
Horizon Pharma
Immunovaccine Inc.
Innovus Pharma
Lpath Inc.
Mast Therapeutics
Matinas BioPharma
Newron Pharmaceuticals SpA
NovaBay Pharmaceuticals
Ocera Inc.
OncoMed Pharmaceuticals*
OncoSec Medical
Palatin Technologies
Radius Health*
Rexahn Pharmaceuticals
RXi Pharmaceuticals
Trovagene, Inc.
TxCell SA
*Denotes companies who went public since passage of the JOBS Act

Now a staple at the BIO Investor Forum, the event will again host a series of Discovery Track presentations that feature Seed and A-round companies incorporated after 2009 and have raised less than $25M through October 2014. Companies in this track are also first-time presenters and use biotechnology or related technologies for research and development of drug products or diagnostics. The following companies are scheduled to present in the Discovery Track:

Aeglea BioTherapeutics
Allinky Biopharma
Bell Biosystems
Bioniz LLC
BioNovion B.V.
Biscayne Pharmaceuticals
Corbus Pharmaceuticals
ETX Pharma, Inc.
GrayBug LLC
Humanetics Corp.
Makindus Inc.
MentiNova, Inc.
Recursion Pharmaceuticals
Relburn-Metabolomics Inc.
Stemsynergy Therapeutics
Tunitas Therapeutics
Tute Genomics

Also presenting in the Discovery Track will be several patient advocacy groups looking for potential research partners:

Juvenile Diabetes Research Foundation
Rare Cancer Research Foundation

New to BIO Investor Forum this year, the Buzz of BIO contest is recognizing "Early Stage Entrepreneurs" and "Late Stage Leaders." One winner from each category will receive complimentary registration and a company presentation opportunity. Voting opens today, August 25, and winners will be selected by number of votes, on September 4, 2014. Nominees include:

Early Stage Entrepreneur:
Bell Biosystems
BioAegis Therapeutics
BNOAT Oncology
Inhibrx LLC
NanoSomiX Inc.
Synergys Biotherapeutics
Targeson, Inc.
Xcell Biosciences

Late Stage Leader:
Avedro Inc.
CorMatrix Cardiovascular
Enable Injections, LLC
Forsight Vision5
KineMed, Inc.
Tobira Therapeutics
Trevi Therapeutics

To learn more about the BIO Investor Forum, including registration, program and partnering information, please visit here. Media registration is now open for qualified members of the press.

About BIO

BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world's largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIO produces BIOtechNOW, an online portal and monthly newsletter chronicling "innovations transforming our world." Subscribe to BIOtechNOW.

Upcoming BIO Events

BIO Latin America Conference
September 9-11, 2014
Rio de Janeiro, Brazil

Livestock Biotech Summit
September 16-18, 2014
Sioux Falls, SD

BIO Investor Forum
October 7-8, 2014
San Francisco, CA

BIO Europe 2014
November 3-5, 2014
Frankfurt, Germany

BIO IPCC Conference
November 10-12, 2014
Nashville, TN

BIO Pacific Rim Summit on Industrial Biotechnology & Bioenergy
December 7-9, 2014
San Diego, CA

BIO International Convention
June 15-18, 2015
Philadelphia, PA

[ Back To NFVZone's Homepage ]